1. Home
  2. SPRO vs INVE Comparison

SPRO vs INVE Comparison

Compare SPRO & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.79

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Logo Identiv Inc.

INVE

Identiv Inc.

HOLD

Current Price

$4.10

Market Cap

115.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
INVE
Founded
2013
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
135.5M
115.7M
IPO Year
2017
1997

Fundamental Metrics

Financial Performance
Metric
SPRO
INVE
Price
$2.79
$4.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$5.50
AVG Volume (30 Days)
663.0K
171.3K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
$60,219,000.00
Revenue This Year
N/A
$22.10
Revenue Next Year
$300.00
$20.74
P/E Ratio
N/A
N/A
Revenue Growth
39.24
7.21
52 Week Low
$1.80
$3.08
52 Week High
$3.09
$5.30

Technical Indicators

Market Signals
Indicator
SPRO
INVE
Relative Strength Index (RSI) 55.64 46.44
Support Level $2.18 $3.24
Resistance Level $2.90 $4.07
Average True Range (ATR) 0.17 0.25
MACD 0.03 -0.07
Stochastic Oscillator 58.45 26.24

Price Performance

Historical Comparison
SPRO
INVE

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About INVE Identiv Inc.

Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.

Share on Social Networks: